Amphastar Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) on July 13, 2026, reporting events that occurred on July 9, 2026. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased the authorized number of directors from 10 to 11.
- New Appointment: Anthony Pierce was appointed as a Class III director, effective immediately, serving until the 2028 annual meeting of stockholders.
- Independence: The Board determined Mr. Pierce is independent under Nasdaq listing standards.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. The document details the compensatory arrangements for the new director:
- Cash Retainer: $55,000 annually (pro-rated for the start date).
- Equity Grant: Aggregate grant date fair value of $300,000, consisting of 50% restricted stock units and 50% stock options.
- Vesting: Equity vests on the first anniversary of the grant date, subject to continued service.
- Indemnification: The Company will enter into its standard form of indemnification agreement with Mr. Pierce.
Key Facts for Investor Verification
- Verify the total number of directors on the Board is now 11.
- Confirm Anthony Pierce's independence status and lack of conflicting relationships.
- Review the Company's Proxy Statement on Schedule 14A (filed April 13, 2026) for details on the standard non-employee director compensation plan referenced in this filing.
- Note that no financial performance data is included in this specific 8-K filing.